Literature DB >> 1962057

The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease.

J P Blass1, G E Gibson.   

Abstract

Several lines of evidence suggest that abnormalities in oxidative metabolism and specifically in mitochondria may play an important role in Alzheimer's disease. Abnormalities of oxidative metabolism exist in this disorder. They have been demonstrated in brain studied in vivo, ex vivo (biopsies), at autopsy, and in non-neural tissues including cultured cells. The abnormalities include a profound deficit in the activity of the ketoglutarate dehydrogenase complex (KGDHC), which is likely to lead to impaired metabolism of glutamate and might contribute to selective neuronal cell death by excitotoxic mechanisms as well as by direct effects on energy metabolism through its role in the tricarboxylic acid cycle. Abnormalities in oxidative metabolism may be related to the pathophysiology of Alzheimer's disease by plausible mechanisms for which there is evidence at least in model systems. Hypoxia is known to induce neuropsychological impairments analogous to those which occur in dementing syndromes. Brain, and specifically neurons, are likely to be particularly vulnerable to impairments of oxidative metabolism because of their demonstrated tight dependence on continuous oxidation of glucose to maintain their structure and function. Neuroanatomic studies as well as recent data from CT, PET, and SPECT scanning agree with formulations that suggest the brain areas of greatest vulnerability in Alzheimer's disease include those particularly sensitive to oxidative impairments. Although the mechanisms of accumulation of the classical neuropathological hallmarks of Alzheimer's disease (paired helical filaments, amyloid plaques) are not known, experimental data suggest that metabolic stresses may contribute to the accumulation of these materials. These data include the accumulation of immunoreactivity of anti-paired helical filament antibodies in cells exposed to a mitochondrial poison, the uncoupler CCCP. Impairments of oxidative metabolism are known to impair the metabolism of neurotransmitters involved in Alzheimer's disease; the synthesis of acetylcholine, which is characteristically involved, is exquisitely sensitive to oxidative abnormalities. Experimental evidence suggests that abnormalities of cellular calcium homeostasis, which have been demonstrated in Alzheimer cells, may mediate key deleterious effects of the abnormalities in oxidative metabolism in this disorder. Experimental studies in animals indicate that age potentiates the effects of inherent oxidative abnormalities on the brain, as does cerebrovascular disease. These observations might help to explain the increasing clinical expression of the gene for Alzheimer's disease with age. They are also in accord with difficulties in separating the role of vascular from that of inherent degenerative factors in dementia of later onset. Treatment with L-carnitine, a manipulation designed to mitigate consequences of a mitochondrial abnormality, normalized several non-mitochondrial abnormalities in cultured Alzheimer cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1962057

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  30 in total

Review 1.  The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides.

Authors:  Andrey Y Abramov; Michael R Duchen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-12-29       Impact factor: 6.237

Review 2.  Mitophagy and Alzheimer's Disease: Cellular and Molecular Mechanisms.

Authors:  Jesse S Kerr; Bryan A Adriaanse; Nigel H Greig; Mark P Mattson; M Zameel Cader; Vilhelm A Bohr; Evandro F Fang
Journal:  Trends Neurosci       Date:  2017-02-09       Impact factor: 13.837

3.  Mitochondrial abnormalities in Alzheimer's disease.

Authors:  K Hirai; G Aliev; A Nunomura; H Fujioka; R L Russell; C S Atwood; A B Johnson; Y Kress; H V Vinters; M Tabaton; S Shimohama; A D Cash; S L Siedlak; P L Harris; P K Jones; R B Petersen; G Perry; M A Smith
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

4.  Regional membrane phospholipid alterations in Alzheimer's disease.

Authors:  M R Prasad; M A Lovell; M Yatin; H Dhillon; W R Markesbery
Journal:  Neurochem Res       Date:  1998-01       Impact factor: 3.996

5.  Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease.

Authors:  M Gold; R A Hauser; M F Chen
Journal:  Metab Brain Dis       Date:  1998-03       Impact factor: 3.584

Review 6.  Alzheimer's disease and cholesterol: the fat connection.

Authors:  Laura Canevari; John B Clark
Journal:  Neurochem Res       Date:  2006-12-27       Impact factor: 3.996

7.  Induction of nitric oxide synthase and microglial responses precede selective cell death induced by chronic impairment of oxidative metabolism.

Authors:  N Y Calingasan; L C Park; L L Calo; R R Trifiletti; S E Gandy; G E Gibson
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

8.  Solution structure and characterisation of the human pyruvate dehydrogenase complex core assembly.

Authors:  S Vijayakrishnan; S M Kelly; R J C Gilbert; P Callow; D Bhella; T Forsyth; J G Lindsay; O Byron
Journal:  J Mol Biol       Date:  2010-03-31       Impact factor: 5.469

Review 9.  Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer's disease.

Authors:  Rosella Abeti; Michael R Duchen
Journal:  Neurochem Res       Date:  2012-10-18       Impact factor: 3.996

10.  Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats.

Authors:  Gjumrakch Aliev; Jiankang Liu; Justin C Shenk; Kathryn Fischbach; Gerardo J Pacheco; Shu G Chen; Mark E Obrenovich; Walter F Ward; Arlan G Richardson; Mark A Smith; Eldar Gasimov; George Perry; Bruce N Ames
Journal:  J Cell Mol Med       Date:  2008-03-28       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.